Indeed, genetic Thp1 ablation or pharmacological inhibition of THP1 protects against obesity, insulin resistance, and fatty liver disease in mice fed an HFD, while increasing the overall metabolic expenditure. This evidence concerns the gene GLI2 and obesity disorder.